{
    "clinical_study": {
        "@rank": "83986", 
        "arm_group": [
            {
                "arm_group_label": "LIK066 Dose 1/Placebo/LIK066 Dose 2/LIK066 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Period 1- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 Dose 2 treatment once daily (q.d.) for 4 days. Period 4- LIK066 Dose 3 treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods."
            }, 
            {
                "arm_group_label": "LIK066 Dose 2/LIK066 Dose 1/LIK066 Dose 3/Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Period 1- LIK066 Dose 2 treatment once daily (q.d.) for 4 days. Period 2- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. Period 3 - LIK066 Dose 3 treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days . 14 days washout periods between treatment periods."
            }, 
            {
                "arm_group_label": "LIK066 Dose 3/ LIK066 Dose 2/Placebo/LIK066 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Period 1- LIK066 Dose 3 treatment once daily (q.d.) for 4 days. Period 2- LIK066 Dose 2 treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods."
            }, 
            {
                "arm_group_label": "Placebo/LIK066 Dose 3/LIK066 Dose 1/LIK066 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 Dose 3 treatment once daily (q.d.) for 4 days. Period 3- LIK066 Dose 1 treatment once daily (q.d.) for 4 days. Period 4- LIK066 Dose 2 treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the effect of LIK066 on intestinal glucose absorption\n      immediately after a single dose (immediate effect) and 6 hours following the dose (after\n      multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM)."
        }, 
        "brief_title": "Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients, age 18-65 years, must have been diagnosed with T2DM at least 6 months prior\n             to screening with HbA1c 6.5 to 10.0%, inclusive, at screening.\n\n          -  Fasting plasma glucose \u2264250mg/dL at screening.\n\n          -  If treated with metformin, patients must be on a stable dose for 12 weeks prior to\n             randomization and maintain the dose until the end of the study.\n\n        Exclusion Criteria:\n\n          -  Patients with type 1 diabetes mellitus.\n\n          -  Patients with history of acute diabetic complications within the 6 months prior to\n             screening.\n\n          -  Pregnant or nursing (lactating) women.\n\n          -  Women of child-bearing potential unless they are using effective methods of\n             contraception during dosing of study treatment.\n\n          -  Patients with signs or symptoms of significant diabetic complications.\n\n          -  Patients treated with certain blood pressure or lipid lowering medications unless\n             patients have been on stable doses for the 12 weeks prior to dosing.\n\n          -  History of drug or alcohol abuse within the 12 months prior to dosing.\n\n          -  Any surgical or medical condition, acute or unstable chronic disease which may, based\n             on the investigator's opinion, jeopardize the patient in case of participation in the\n             study.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915849", 
            "org_study_id": "CLIK066A2201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LIK066 Dose 1/Placebo/LIK066 Dose 2/LIK066 Dose 3", 
                    "LIK066 Dose 2/LIK066 Dose 1/LIK066 Dose 3/Placebo", 
                    "LIK066 Dose 3/ LIK066 Dose 2/Placebo/LIK066 Dose 1", 
                    "Placebo/LIK066 Dose 3/LIK066 Dose 1/LIK066 Dose 2"
                ], 
                "intervention_name": "LIK066", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LIK066 Dose 1/Placebo/LIK066 Dose 2/LIK066 Dose 3", 
                    "LIK066 Dose 2/LIK066 Dose 1/LIK066 Dose 3/Placebo", 
                    "LIK066 Dose 3/ LIK066 Dose 2/Placebo/LIK066 Dose 1", 
                    "Placebo/LIK066 Dose 3/LIK066 Dose 1/LIK066 Dose 2"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chula Vista", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91910"
                }, 
                "name": "Novartis Investigative Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blinded, Placebo-controlled, Crossover Trial to Assess the Effect of Orally Administered LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The effect of single dose (day 1) and multiple doses (day 4) will be assessed", 
            "measure": "Area under the postprandial curve (AUC) for rate of appearance (Ra) of exogenous glucose", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}